Pulmonary Arterial Hypertension & increased dose of Opsumit


Trial Objective

The UNISUS study will compare the effectiveness and safety of a higher dose of an investigational medication called Opsumit to a lower dose in people with pulmonary arterial hypertension (PAH). The results of the UNISUS Study will provide more information about the investigational medication’s effectiveness and safety when it is given as a higher dose to adults with PAH. Participants will be randomly assigned to receive a tablet of 10 mg or 75 mg dose of Opsumit to take once a day. During clinic visits, participants may have their vital signs taken, provide a blood sample and perform a walking test.


Active Clinical Trials Currently Recruiting

Who Can Participate

Patients diagnosed with pulmonary arterial hypertension

Age: 18+    Gender: Any Gender

Estimated Time Commitment

Up to 4 years. Year 1: monthly visits. Year 2: visits every three months. Years 3-4: visits every six months.

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Jennifer Underwood

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Janssen Pharmaceuticals


Request More Information

By completing this form, you agree to learn more about this study and see if you qualify.

 I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: